#USA #biotech #GenScript #Piscataway #AI Drug Discovery

GenScript Achieves Impressive Revenue Growth

GenScript Biotech Corporation, listed on the Hong Kong Stock Exchange, has announced a substantial increase in revenue for the first half of 2026. The company reported almost $404.2 million in revenue, marking a year-over-year growth of 27.3%. This impressive performance is a clear indicator of GenScript's strong market presence and operational efficiency.

The driving force behind this growth has been the rapid advancement of its AI-enabled drug discovery services, which have notably doubled compared to the previous year. This segment has now become a pivotal part of GenScript’s revenue model, as it responds to the burgeoning demand from pharmaceutical companies and biotech firms eager to harness the power of artificial intelligence in drug development.

Gene-to-Protein Platform Leading Revenue

Within GenScript's revenue streams, the Gene-to-Protein platform has emerged as a powerhouse, contributing about 66% of the overall sales from the Life Science Group. This platform synergistically blends scientific expertise, automation, and manufacturing capability, demonstrating the company's strategy to streamline the drug development process from initial discovery through production support. Traditional timelines for drug candidate validation are shrinking thanks to the combined capabilities enabled by AI, allowing for greater speed and reliability.

Sherry Shao, GenScript's Rotating CEO, commented on these figures, stating, "Our first-half results illustrate our ability to execute effectively across our portfolio. The growth of our core business sectors has led to both increased revenue and enhanced profitability. We foresee significant long-term opportunities in the life sciences sector as AI continues to transform this landscape. Our ongoing enhancements in our Gene-to-Protein platform and overall operational capabilities position us as a vital partner for AI-driven drug discovery."

Performance Highlights of First-Half 2026

• - The GenScript Life Science Group reported revenues close to $319 million, reflecting a growth of 28.8%.
• - Adjusted gross profit surged approximately 46.1% to reach around $184.5 million, while adjusted operating profit skyrocketed to $94 million, up 102.8%.
• - ProBio, another division of GenScript, reported a comparable revenue rise of 34.2%, achieving around $61.1 million. This segment also noted a significant increase in new orders by 54%, hinting at a robust future.
• - Bestzyme, another sector of the company, saw revenues rise by 7.4%, demonstrating consistent performance amidst a transformative market.

Investments in Future Technologies

The dynamics within the biopharmaceutical research arena are shifting, with AI playing an increasingly central role. As the complexity of drug designs escalates, the need for integrated scientific infrastructure that can deliver comprehensive drug-development support grows greater. GenScript is strategically investing in its operational framework to facilitate this evolution, enhancing automation, digital workflows, and manufacturing capabilities globally.

ProBio is on track to capitalize on the growing interest in biologics development, bolstered by its tightening operational performance and expanding order backlogs. Bestzyme is keen on continuing its journey by innovating fabrication technologies and integrating AI to boost efficiency and product development speeds.

Future Outlook

As GenScript moves into the latter half of 2026, the company has clear momentum in its strategies across various business lines. With an expanding customer base and increasing utilization of its manufacturing capabilities, further revenue growth is anticipated.

The company's continuous investments in technology and capacity extend its ability to address complex drug discovery demands, reaffirming GenScript’s role as a foundational infrastructure partner for next-generation therapeutic advancements. As the adoption of AI grows, GenScript is laid out to deepen client relationships while bolstering its delivery mechanisms, securing its place as a leading force in biotech innovation.

For those interested in detailed financial reports and segment information, GenScript's complete first-half review for 2026 is available via their announcement on the Stock Exchange of Hong Kong and on their official website.

About GenScript Biotech Corporation

Founded in New Jersey in 2002, GenScript plays a crucial role in supporting biotechnology innovation. With a mission to enhance health through biotechnology, GenScript operates globally, employing over 6,100 professionals to assist more than 200,000 clients across 100 countries.

For more information, visit www.genscript.com.